Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis.

Research unit

INNOSUISSE

Project number

100.087 IP-LS

Project title

Preclinical development of an innovative drug candidate, TOP-V122, for the treatment of lung fibrosis. (Innolink: 100.087 IP-LS)

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Idiopathic pulmonary fibrosis (IPF) is a form of restrictive interstitial lung disease (ILD) associated with extremely poor outcomes. With our approach based on a unique mode of action drug that restores cGMP levels, we aim to stop lung fibrosis progression and increase the survival rate.